Terms: = Head and neck cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S
233 results:
1. Circ_0098823 binding with IGF2BP3 regulates DNM1L stability to promote metastasis of hepatocellular carcinoma via mitochondrial fission.
Yan J; Wang X; Fan Z; Xu Y; Zhang Y; Liu Y; Guo L; Liu D
Apoptosis; 2024 Jun; 29(5-6):709-725. PubMed ID: 38459420
[TBL] [Abstract] [Full Text] [Related]
2. Exploration and validation of key genes associated with early lymph node metastasis in thyroid carcinoma using weighted gene co-expression network analysis and machine learning.
Liu Y; Yin Z; Wang Y; Chen H
Front Endocrinol (Lausanne); 2023; 14():1247709. PubMed ID: 38144565
[TBL] [Abstract] [Full Text] [Related]
3. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven cancers: Implications for HER2-her3-specific Versus Pan-HER Targeting Strategies.
Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
[TBL] [Abstract] [Full Text] [Related]
4. Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal.
Lu Y; Zhao Y; Liu P; Xu X
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37643458
[TBL] [Abstract] [Full Text] [Related]
5. Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating her3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways.
Dang H; Sui M; He Q; Xie J; Liu Y; Hou P; Ji M
Int J Biol Macromol; 2023 Sep; 248():125867. PubMed ID: 37473892
[TBL] [Abstract] [Full Text] [Related]
6. A phase Ia/Ib study of novel anti-erbb3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer.
Seo S; Keam B; Shin SH; Chae YS; Kim TM; Park LC; Hong SB; Ahn MJ; Kim SB
Int J Cancer; 2023 Oct; 153(8):1501-1511. PubMed ID: 37357950
[TBL] [Abstract] [Full Text] [Related]
7. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, her3/4 mutation or KRAS mutation.
Piha-Paul SA; Tseng C; Tran HT; Gao M; Karp DD; Subbiah V; Tsimberidou AM; Kawedia JD; Fu S; Pant S; Yap TA; Morris VK; Kee BK; Blum Murphy M; Lim J; Meric-Bernstam F
Cancer Chemother Pharmacol; 2023 Aug; 92(2):107-118. PubMed ID: 37314501
[TBL] [Abstract] [Full Text] [Related]
8. Indications for elective neck dissection in cT1N0M0 oral cavity cancer according to the AJCC eight edition: A nationwide study.
Chien CY; Wang CP; Lee LY; Lee SR; Ng SH; Kang CJ; Lin JC; Terng SD; Hua CH; Chen TM; Chen WC; Tsai YT; Tsai CY; Chu YH; Lin CY; Fan KH; Wang HM; Hsieh CH; Yeh CH; Lin CH; Tsao CK; Cheng NM; Fang TJ; Huang SF; Lee LA; Fang KH; Wang YC; Lin WN; Hsin LJ; Yen TC; Wen YW; Liao CT
Oral Oncol; 2023 May; 140():106366. PubMed ID: 36965411
[TBL] [Abstract] [Full Text] [Related]
9. Disulfiram/Cu Kills and Sensitizes
Xie J; Liu J; Zhao M; Li X; Wang Y; Zhao Y; Cao H; Ji M; Chen M; Hou P
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834830
[No Abstract] [Full Text] [Related]
10. Influence of Hashimoto thyroiditis on diagnosis and treatment of thyroid nodules.
Mao L; Zheng C; Ou S; He Y; Liao C; Deng G
Front Endocrinol (Lausanne); 2022; 13():1067390. PubMed ID: 36619577
[TBL] [Abstract] [Full Text] [Related]
11. Response to Neoadjuvant Targeted Therapy in Operable head and neck cancer Confers Survival Benefit.
Mascarella MA; Olonisakin TF; Rumde P; Vendra V; Nance MA; Kim S; Kubik MW; Sridharan SS; Ferris RL; Fenton MJ; Clayburgh DR; Ohr JP; Joyce SC; Sen M; Herman JG; Grandis JR; Zandberg DP; Duvvuri U
Clin Cancer Res; 2023 Feb; 29(4):723-730. PubMed ID: 36595540
[TBL] [Abstract] [Full Text] [Related]
12. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
Garcia-Rendueles MER; Krishnamoorthy G; Saqcena M; Acuña-Ruiz A; Revilla G; de Stanchina E; Knauf JA; Lester R; Xu B; Ghossein RA; Fagin JA
Mol Cancer; 2022 Dec; 21(1):213. PubMed ID: 36476495
[TBL] [Abstract] [Full Text] [Related]
13. Radioactive Iodine-Refractory Pulmonary Metastases of Papillary Thyroid cancer in Children, Adolescents, and Young Adults.
Tian T; Huang S; Dai H; Qi M; Liu B; Huang R
J Clin Endocrinol Metab; 2023 Jan; 108(2):306-314. PubMed ID: 36226635
[TBL] [Abstract] [Full Text] [Related]
14. HER2 and her3 as Therapeutic Targets in head and neck cancer.
Saddawi-Konefka R; Schokrpur S; Lui AJ; Gutkind JS
Cancer J; 2022 Sep-Oct 01; 28(5):339-345. PubMed ID: 36165721
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive Molecular Profiling of Oncocytic Salivary Gland Malignancies.
Zaccarini DJ; Sivapiragasam A; Sokol E; Huang RSP; Pavlick DC; Janovitz T; Nasr MR; Ross JS
Appl Immunohistochem Mol Morphol; 2022 Oct; 30(9):609-613. PubMed ID: 35876752
[TBL] [Abstract] [Full Text] [Related]
16. Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome.
Viktorsson K; Hååg P; Shah CH; Franzén B; Arapi V; Holmsten K; Sandström P; Lewensohn R; Ullén A
Mol Oncol; 2022 Oct; 16(20):3620-3641. PubMed ID: 35838333
[TBL] [Abstract] [Full Text] [Related]
17. The Prediction of a 3-Protein-Based Model on the Prognosis of head and neck Squamous Cell Carcinoma.
Chen X; Wong K; Li Y; Guan Z
Comput Math Methods Med; 2022; 2022():2161122. PubMed ID: 35756403
[TBL] [Abstract] [Full Text] [Related]
18. Search for New Target Genes of MicroRNA for Differential Diagnosis of Benign and Malignant Neoplasms of the Thyroid Gland by In Silico Methods.
Kononchuk VV; Kopeikina EV; Kalinina TS; Saik OV; Alekseenok EY; Kolyagina MK; Matashova VA; Shevchenko SP; Gulyaeva LF; Kushlinskii NE
Bull Exp Biol Med; 2022 Jun; 173(2):246-251. PubMed ID: 35737153
[TBL] [Abstract] [Full Text] [Related]
19. Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review.
Blangé D; Stroes CI; Derks S; Bijlsma MF; van Laarhoven HWM
Cancer Treat Rev; 2022 Jul; 108():102418. PubMed ID: 35689885
[TBL] [Abstract] [Full Text] [Related]
20. Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
Yang Z; Liao J; Schumaker L; Carter-Cooper B; Lapidus RG; Fan X; Gaykalova DA; Mehra R; Cullen KJ; Dan H
Oral Oncol; 2022 Aug; 131():105939. PubMed ID: 35667295
[TBL] [Abstract] [Full Text] [Related]
[Next]
